Results 151 to 160 of about 170,525 (342)

Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. [PDF]

, 2017
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality.
Aby, Elizabeth, Agopian, Vatche, Busuttil, Ronald W, French, Samuel W, Grotts, Jonathan F, Jimenez, Melissa A, Saab, Sammy   +6 more
core   +1 more source

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Gastroenterology, 2016
BACKGROUND & AIMS Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
V. Ratziu, S. Harrison, S. Francque, P. Bedossa, P. Lehert, L. Serfaty, M. Romero‐Gomez, J. Boursier, M. Abdelmalek, Steve Caldwell, J. Drenth, Q. Anstee, D. Hum, Rémy Hanf, A. Roudot, S. Megnien, B. Staels, A. Sanyal   +17 more
semanticscholar   +1 more source

Predicting Postresection Colorectal Liver Metastases Recurrence Using Advanced Graph Neural Networks with Explainability and Causal Inference

Advanced Intelligent Systems, EarlyView.
This study introduces a framework that combines graph neural networks with causal inference to forecast recurrence and uncover the clinical and pathological factors driving it. It further provides interpretability, validates risk factors via counterfactual and interventional analyses, and offers evidence‐based insights for treatment planning ...
Jubair Ahmed, Md. Abdur Rahman, Mohaimenul Azam Khan Raiaan, Sami Azam   +3 more
wiley   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman, Victoria E. Parker, Carmel M. McEniery, Giovanni Di Stefano, Annette Hubsch, Evangelia Vamvaka, Jo Helmy, Fotini Kaloyirou, Navazh Jalaludeen, Peter Barker, Lutz Jermutus, Joseph Cheriyan, Philip Ambery, Ian B. Wilkinson   +13 more
wiley   +1 more source

Evaluation of liver stiffness measurement–based scores in liver transplantation recipients

Liver Transplantation, EarlyView., 2022
Abstract Combining bioclinical parameters with liver stiffness measurement (LSM) has improved the diagnostic performance of vibration‐controlled transient elastography (VCTE) for detection of advanced fibrosis in patients with chronic liver disease. However, this approach has not yet been tested in liver transplantation (LT) recipients.
Tamoore Arshad, Chandra S. Bhati, Anh T. Bui, Michael Tseng, Dylan Vainer, Austin Miller, Marie‐Claire Evans, Taseen Syed, Vaishali Patel, Michael O. Idowu, Mark Muthiah, Mohammad Shadab Siddiqui   +11 more
wiley   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Корекція ендотоксикозу і синдрому пероксидації у хворих на подагру в поєднанні з неалкогольним стеатогепатитом = Lipid peroxidation and endotoxemia syndrome сorrection in patients with gout combined with nonalcoholic steatohepatitis

Journal of Education, Health and Sport, 2015
Smiyan S. I., Danchak S. V. Корекція ендотоксикозу і синдрому пероксидації у хворих на подагру в поєднанні з неалкогольним стеатогепатитом = Lipid peroxidation and endotoxemia syndrome сorrection in patients with gout combined with nonalcoholic ...
S. I. Smiyan, S. V. Danchak
doaj  

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review

Терапевтический архив
In September 2023, the European Association for the Study of the Liver (EASL) updated the disease nomenclature for non-alcoholic (metabolically associated) fatty liver disease.
Chavdar S. Pavlov, Daria A. Teplyuk, Leonid B. Lazebnik, Aleksandr S. Ametov, Evgeniia Yu. Pashkova, Sergey M. Sorokoletov, Yury P. Uspenskiy, Svetlana V. Turkina, Elizaveta V. Ponomarenko, Aleksandr S. Maslakov   +9 more
doaj   +1 more source

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Nature Network Boston, 2021
S. Harrison, P. Ruane, B. Freilich, G. Neff, R. Patil, C. Behling, Chen-bo Hu, Erica Fong, Brittany de Temple, Erik J. Tillman, T. Rolph, Andrew Cheng, Kitty Yale   +12 more
semanticscholar   +1 more source

Quantitative Approaches to Accelerate MASH Drug Discovery and Development

Clinical Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis (MASH) is a widespread liver condition that leads to cirrhosis, hepatic carcinoma, and increased mortality rates. In MASH, the diagnosis and accelerated approval of drugs are dependent on changes in histological endpoints; full approval requires lengthy outcomes trials.
Yasmeen Abouelhassan, Shailendra Tallapaka, Ramin Mehrani, Scott Q. Siler, Li Qin, Zeyuan Wang, Maria E. Trujillo   +6 more
wiley   +1 more source